NASDAQ:CTIC CTI BioPharma Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CTI BioPharma Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.05 0.00 (0.00 %) (As of 09/29/2020 12:00 AM ET) Add Compare Share Today's Range$1.02Now: $1.05▼$1.0650-Day Range$1.02MA: $1.12▼$1.3052-Week Range$0.62Now: $1.05▼$1.95Volume58,389 shsAverage Volume443,352 shsMarket Capitalization$77.40 millionP/E RatioN/ADividend YieldN/ABeta1.44 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; University of Vermont; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingCTI BioPharma has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.50, CTI BioPharma has a forecasted upside of 233.3% from its current price of $1.05.Amount of Analyst CoverageCTI BioPharma has only been the subject of 1 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesCTI BioPharma has received 250 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCTI BioPharma has received 282 “underperform” votes. (Add your “underperform” vote.)Community SentimentCTI BioPharma has received 53.01% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about CTI BioPharma and other stocks. Vote “Outperform” if you believe CTIC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CTIC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCTI BioPharma does not currently pay a dividend.Dividend GrowthCTI BioPharma does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CTI BioPharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.90% of the stock of CTI BioPharma is held by insiders.Percentage Held by Institutions46.75% of the stock of CTI BioPharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of CTI BioPharma is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CTI BioPharma is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCTI BioPharma has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.33 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTIC Previous SymbolNASDAQ:CTICD CUSIPN/A CIK891293 Webwww.ctibiopharma.com Phone206-282-7100Debt Debt-to-Equity Ratio0.04 Current Ratio5.20 Quick Ratio5.20Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.35 million Price / Sales23.11 Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book3.39Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-40,020,000.00 Net MarginsN/A Return on Equity-144.03% Return on Assets-65.99%Miscellaneous Employees46 Outstanding Shares73,717,000Market Cap$77.40 million Next Earnings Date11/2/2020 (Estimated) OptionableOptionable $1.05 0.00 (0.00 %) (As of 09/29/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CTIC News and Ratings via Email Sign-up to receive the latest news and ratings for CTIC and its competitors with MarketBeat's FREE daily newsletter. CTI BioPharma (NASDAQ:CTIC) Frequently Asked Questions How has CTI BioPharma's stock been impacted by COVID-19? CTI BioPharma's stock was trading at $0.8901 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CTIC shares have increased by 18.0% and is now trading at $1.05. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of CTI BioPharma? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CTI BioPharma. When is CTI BioPharma's next earnings date? CTI BioPharma is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020. View our earnings forecast for CTI BioPharma. How were CTI BioPharma's earnings last quarter? CTI BioPharma Corp (NASDAQ:CTIC) released its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.07. View CTI BioPharma's earnings history. When did CTI BioPharma's stock split? How did CTI BioPharma's stock split work? Shares of CTI BioPharma reverse split on the morning of Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma stock prior to the reverse split would have 10 shares after the split. What price target have analysts set for CTIC? 3 brokers have issued 12 month price objectives for CTI BioPharma's shares. Their forecasts range from $3.00 to $4.00. On average, they expect CTI BioPharma's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 233.3% from the stock's current price. View analysts' price targets for CTI BioPharma. Who are some of CTI BioPharma's key competitors? Some companies that are related to CTI BioPharma include CytomX Therapeutics (CTMX), IMV (IMV), Aldeyra Therapeutics (ALDX), Urovant Sciences (UROV), Concert Pharmaceuticals (CNCE), Cassava Sciences (SAVA), Immunic (IMUX), Osmotica Pharmaceuticals (OSMT), VYNE Therapeutics (VYNE), Selecta Biosciences (SELB), Agile Therapeutics (AGRX), Xeris Pharmaceuticals (XERS), Affimed (AFMD), Arbutus Biopharma (ABUS) and Chiasma (CHMA). View all competitors. What other stocks do shareholders of CTI BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), VBI Vaccines (VBIV), ADMA Biologics (ADMA) and Dynavax Technologies (DVAX). Who are CTI BioPharma's key executives? CTI BioPharma's management team includes the following people: Dr. Adam R. Craig, Pres, CEO, Interim Chief Medical Officer & Director (Age 53)Dr. Jack W. Singer, Co-Founder & Consultant (Age 76)Mr. David H. Kirske, Exec. VP, CFO & Sec. (Age 65)Mr. Bruce J. Seeley, Exec. VP & COO (Age 55)Mr. Ed Bell, Sr. Director of Investor Relations What is CTI BioPharma's stock symbol? CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC." How do I buy shares of CTI BioPharma? Shares of CTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is CTI BioPharma's stock price today? One share of CTIC stock can currently be purchased for approximately $1.05. How big of a company is CTI BioPharma? CTI BioPharma has a market capitalization of $77.40 million and generates $3.35 million in revenue each year. CTI BioPharma employs 46 workers across the globe. What is CTI BioPharma's official website? The official website for CTI BioPharma is www.ctibiopharma.com. How can I contact CTI BioPharma? CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-282-7100 or via email at [email protected] This page was last updated on 9/29/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
